QS Investors’s Syndax Pharmaceuticals SNDX Stock Holding History

QS Investors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,207	Closed	-$6K	–	1845
2018 Q4	$6K	Buy	+1,207	New	+$6.62K	﹤0.01%	1560

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

QS Investors's SNDX Position: Q1 2019 in Review

QS Investors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2019, closing a stake of 1,207 shares — an estimated $6K sold.

QS Investors first reported a position in SNDX in Q4 2018 and held it in 1 quarter. The position peaked at $6K in Q4 2018. 69 funds tracked by Wall St. Rank hold SNDX as of Q1 2019.

QS Investors reported no remaining Syndax Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
QS Investors sold 1,207 Syndax Pharmaceuticals shares in Q1 2019, an estimated $6K.
QS Investors first reported a position in Syndax Pharmaceuticals in Q4 2018 and held it in 1 quarter.
QS Investors's Syndax Pharmaceuticals position peaked at $6K in Q4 2018.
69 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2019.

Based on QS Investors's 13F filing for Q1 2019, filed 15 May 2019.